StockNews.AI
SLNO
StockNews.AI
7 mins

INVESTOR ALERT: Investigation of Soleno Therapeutics, Inc. (SLNO) Announced by Holzer & Holzer, LLC

1. Holzer & Holzer investigates Soleno Therapeutics for potential securities law violations. 2. Scorpion Capital's report claims Soleno's clinical trials lack credibility. 3. Following the report, SLNO's stock price experienced a decline. 4. Investors affected by losses are urged to seek legal consultation. 5. Holzer & Holzer specializes in shareholder litigation against corporate misconduct.

3m saved
Insight
Article

FAQ

Why Bearish?

The allegations about SLNO's clinical trials directly undermine investor confidence, leading to stock price drops. Historical examples show similar situations led to prolonged stock declines in biotech firms.

How important is it?

The investigation and negative report could lead to legal actions impacting SOLNO's market reputation and investor trust.

Why Short Term?

The immediate reaction to the report is significant, but outcomes from investigations could influence long-term perception.

Related Companies

VYKAT
ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Soleno Therapeutics, Inc. (“Soleno Therapeutics” or the “Company”) (NASDAQ: SLNO) complied with federal securities laws. On August 15, 2025, Scorpion Capital released a report alleging, among other things, that Soleno Therapeutics’ phase 3 clinical trials and withdrawal studies conducted in furtherance of the Company’s efforts to obtain approval of its drug, VYKAT™ XR, “lack credibility and were plagued with numerous problems.” Following this report, the price of the Company’s stock dropped. If you purchased Soleno Therapeutics stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/soleno-therapeutics/ to discuss your legal rights. Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content. CONTACT:  Corey Holzer, Esq.(888) 508-6832 (toll-free) cholzer@holzerlaw.com

Related News